Overview

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

Status:
Not yet recruiting

Trial end date:
2023-08-08

Target enrollment:

Participant gender:

Summary

The primary objectives for the study are: - Part I and Part II: Assess safety and tolerability of repeated doses of INDV-2000 in healthy volunteers. - Part III: Assess the safety and tolerability of repeated doses of INDV-2000 administered alone and with SUBOXONE sublingual (SL) film in an opioid use disorder (OUD) treatment seeking population.

Phase:

Phase 1

Details

Lead Sponsor:

Indivior Inc.

Treatments:

Buprenorphine
Buprenorphine, Naloxone Drug Combination
Naloxone